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Introduction
Malignant pleural mesothelioma (MPM) is an incurable
malignant disease that results mostly from chronic expo-
sition to asbestos. Fibroblast activation protein (FAP) is
predominantly expressed on the surface of reactive
tumor-associated fibroblasts and on particular cancer
types. Therefore, FAP is an attractive target for adoptive
T cell therapy. T cells can be re-directed by gene transfer
of FAP-specific chimeric antigen receptors (CAR).
Methods
Immunohistochemistry was performed on tumor tissue
from MPM patients to evaluate FAP expression. CD8+
human T cells were retrovirally transduced with an anti-
FAP-F19-ΔCD28/CD3ζ-CAR constructs. T cell function
was evaluated by cytokine release and cytotoxicity assays
in vitro. In vivo function was tested with an intraperito-
neal xenograft tumor model.
Results
FAP was found to be expressed in all subtypes of MPM.
FAP expression was evaluated in healthy adult tissue
samples and detected in pancreas and placenta. FAP-
specific re-directed T cells lysed FAP positive mesothe-
lioma cells and inflammatory fibroblasts in an antigen-
specific manner in vitro. FAP-specific re-directed T cells
inhibited the growth of FAP positive human tumor cells
in the peritoneal cavity of mice and significantly pro-
longed survival of mice. We plan to adoptively transfer
re-directed T cells into the pleural cavity of MPM
patients treated with chemotherapy. Cytokine analysis of
pleural effusions from patients revealed presence of TGF-
b1, VEGF, IL-6, and IL-10. Incubation of re-directed
T cells with pleural effusions resulted in suppressed
antigen-specific IFNg secretion in 2 of 9 cases. FAP speci-
fic re-directed T cells were incubated with chemothera-
peutic agents at reported plasma peak concentrations. No
decrease in IFNg secretion was detected for pemetrexed.
Higher concentrations of cisplatin reduced IFNg secretion
by re-directed T cells.
Conclusion
FAP re-directed CD8+ T cells showed antigen-specific
functionality in vitro and in vivo. Furthermore, FAP
expression was verified in all MPM subtypes and IFNg
secretion of re-directed T cells was not hampered in
most cases if incubated with pleural effusions from
patients. Therefore, our data support the conduct of a
phase I clinical trial with adoptively transferred FAP-
specific re-directed T cells in MPM patients.
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